Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JS212 and JS111 in First-Line EGFR-Mutant Advanced NSCLC
NCT07714304Phase 2Not yet recruiting
- Start
- Jul 2026
- Primary completion
- Nov 2026
- Countries
- 1
01
Overview
A Phase 2 trial of JS212, js111 in non-small cell lung cancer (NSCLC). Planned start Jul 2026; status: not yet recruiting.
02
Drugs
JS212js111
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT07714304.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07714304.